Antiestrogen Binding Site and Estrogen Receptor Mediate Uptake and Distribution of 4-Hydroxytamoxifen-Targeted Doxorubicin−Formaldehyde Conjugate in Breast Cancer Cells
Authors:
- 18 November 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (26) , 6509-6518
Abstract
The anthracycline antitumor drug, doxorubicin (DOX), has long been used as a broad spectrum chemotherapeutic. The literature now documents the role of formaldehyde in the cytotoxic mechanism, and anthracycline−formaldehyde conjugates possess substantially enhanced activity in vitro and in vivo. We have recently reported the design, synthesis, and preliminary evaluation of a doxorubicin−formaldehyde conjugate targeted, via 4-hydroxytamoxifen, to the estrogen receptor (ER) and antiestrogen binding site (AEBS), which are commonly present in breast cancer cells. The lead targeted doxorubicin−formaldehyde conjugate, called DOX-TEG-TAM, was found to possess superior cell growth inhibition characteristics relative to clinical doxorubicin and an untargeted control conjugate, especially in ER-negative, multidrug resistant MCF-7/Adr cells. The enhanced activity in the absence of estrogen receptor raised the possibility that targeting was also mediated via AEBS. Fluorescence microscopy of an ER-negative, AEBS-positive cell line as a function of time showed initial DOX-TEG-TAM localization in cytosol, in contrast to initial DOX and untargeted doxorubicin−formaldehyde conjugate localization in the nucleus. DOX-TEG-TAM was taken up by four AEBS-positive cell lines to a greater extent than doxorubicin and an untargeted doxorubicin−formaldehyde conjugate. Of the four cell lines, three were ER negative. DOX-TEG-TAM uptake was inhibited in a dose-dependent manner by the presence of a competing AEBS ligand. DOX-TEG-TAM retains 60% of the affinity of 4-hydroxytamoxifen for AEBS. DOX-TEG-TAM was also taken up by the AEBS-negative, ER-positive cancer cell line Rtx-6; with these cells uptake was inhibited in a dose-dependent manner by the ER ligand, estradiol. The data support the hypothesis that uptake of 4-hydroxytamoxifen targeted doxorubicin−formaldehyde conjugate is mediated by both the antiestrogen binding site and estrogen receptor.Keywords
This publication has 19 references indexed in Scilit:
- Molecular Characterization of the Microsomal Tamoxifen Binding SiteJournal of Biological Chemistry, 2004
- Rational Design and Synthesis of Androgen Receptor-Targeted Nonsteroidal Anti-Androgen Ligands for the Tumor-Specific Delivery of a Doxorubicin−Formaldehyde ConjugateJournal of Medicinal Chemistry, 2003
- Nuclear Targeting and Nuclear Retention of Anthracycline−Formaldehyde Conjugates Implicates DNA Covalent Bonding in the Cytotoxic Mechanism of AnthracyclinesChemical Research in Toxicology, 1999
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Epidoxoform: A Hydrolytically More Stable Anthracycline−Formaldehyde Conjugate Toxic to Resistant Tumor CellsJournal of Medicinal Chemistry, 1998
- Doxoform and Daunoform: Anthracycline−Formaldehyde Conjugates Toxic to Resistant Tumor CellsJournal of Medicinal Chemistry, 1997
- The Overall Partitioning of Anthracyclines into Phosphatidyl‐Containing Model Membranes Depends Neither on the Drug Charge Nor the Presence of Anionic PhospholipidsEuropean Journal of Biochemistry, 1996
- Alkylation of DNA by the Anthracycline, Antitumor Drugs Adriamycin and DaunomycinJournal of Medicinal Chemistry, 1996
- The anti-proliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are notBiochemical Pharmacology, 1990
- Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomersThe Journal of Steroid Biochemistry and Molecular Biology, 1985